APA (7th ed.) Citation

Chin, K. M., Channick, R., Kim, N. H., Ong, R., Turricchia, S., Martin, N., . . . McLaughlin, V. V. (2024). Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies. Cardiology and Therapy, 13(4), 775-796. https://doi.org/10.1007/s40119-024-00386-1

Chicago Style (17th ed.) Citation

Chin, Kelly M., Richard Channick, Nick H. Kim, Rose Ong, Stefano Turricchia, Nicolas Martin, Lada Mitchell, and Vallerie V. McLaughlin. "Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies." Cardiology and Therapy 13, no. 4 (2024): 775-796. https://doi.org/10.1007/s40119-024-00386-1.

MLA (9th ed.) Citation

Chin, Kelly M., et al. "Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies." Cardiology and Therapy, vol. 13, no. 4, 2024, pp. 775-796, https://doi.org/10.1007/s40119-024-00386-1.